AR053020A1 - Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3 - Google Patents

Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3

Info

Publication number
AR053020A1
AR053020A1 ARP060100550A ARP060100550A AR053020A1 AR 053020 A1 AR053020 A1 AR 053020A1 AR P060100550 A ARP060100550 A AR P060100550A AR P060100550 A ARP060100550 A AR P060100550A AR 053020 A1 AR053020 A1 AR 053020A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
cycloalkyl
heteroaryl
aryl
Prior art date
Application number
ARP060100550A
Other languages
English (en)
Original Assignee
Pharmacopeia Drug Discovery
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Drug Discovery, Schering Corp filed Critical Pharmacopeia Drug Discovery
Publication of AR053020A1 publication Critical patent/AR053020A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto que tiene la estructura general expuesta en la formula (1), o sales aceptables para uso farmacéutico, solvatos o ésteres del mismo donde: X es N, O, alquilo, cicloalquilo, alquilcicloalquilo-, heteroarilo, heterociclilo o heterociclenilo; D es un anillo cicloalquilo, cicloalquenilo, arilo, heteroarilo, heterociclenilo o heterociclilo de cinco a nueve miembros donde dicho arilo excluye fenilo y dicho anillo heteroarilo, heterociclenilo y heterociclilo tiene de 0 a 4 heteroátomos seleccionados en forma independiente de O, S y N como átomos anulares, además donde dicho anillo D es no sustituido o se sustituye en forma opcional con 1 a 5 restos R20 seleccionados en forma independiente; R1 y R2 se encuentran independientemente ausentes o presentes, si están presentes cada uno se selecciona en forma independiente del grupo que consiste en H, alquilo, hidroxialquilo, alcoxi, alquenilo, carbonilo, cicloalquilo, alquilcicloalquilo-, hidroxialquilo, cicloalquenilo, alquilarilo, arilalquilo, arilo, amino, alquilamino, amidinilo, alquilamidinilo, carboxamido, ciano, hidroxilo, urea, -N:::CH, =NCN, - (CH2)qOH, -(CH2)qOR31, -(CH2)qNH2, -(CH2)qNHR31, -(CH2)qN(R31)2, - (CH2)qC(=O)NHR31, -(CH2)qSO2R31, -(CH2)qNHSO2R31, -(CH2)qSO2NHR31, -C(=S)N(H)alquilo, -N(H)-S(O)2-alquilo, -N(H)C(=O)N(H)-alquilo, -S(O)2alquilo, -S(O)2N(H)alquilo, -S(O)2N(alquil)2, -S(O)2arilo, -C(=S)N(H)cicloalquilo, -C(=O)N(H)NH2, -C(=O)alquilo, -heteroarilo, heterociclo, y heterociclenilo; o alternativamente cuando X es N, el N tomado junto con R1 y R2 forma un heterociclilo, heteroarilo o -N=C(NH2)2; los restos R3 y R6 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo que consiste en H, alquilo, alquilarilo, aralquilo, -CN, CF3, haloalquilo, cicloalquilo, halogeno, hidroxialquilo, -N=CH-(R31), -C(=O)N(R30)2, -N(R30)2, -OR30, -SO2(R31), -N(R30)C(=O)N(R30)2 y -N(R30)C(=O)R31; los restos R7 y R8 son iguales o diferentes, seleccionándose cada uno en forma independiente del grupo que consiste en H, alquilo, alquilarilo, heteroarilo, hidroxilo, -CN, alcoxi, alquilamino, -N(H)S(O)2alquilo y -N(H)C(=O)N(H)alquilo; o alternativamente R7 y R8 tomados juntos son =O, =S, =NH, =N(alquilo), =N(O alquilo), =N(OH) o cicloalquilo; los restos R10 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo que consiste H, alquilo, cicloalquilo, arilo, heteroarilo, heterociclenilo, heterociclilo, alquilarilo, arilalquilo, -CO2H, hidroxialquilo, -C(=O)N(R30)2, -(CH2)qOH, -(CH2)qOR31, -(CH2)qNHR31, -(CH2)qN(R31)2, -OR30, halogeno, =O, y -C(=O)R31; los restos R11 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo que consiste en H, alquilo, cicloalquilo, arilo, heteroarilo, heterociclilo, heterociclenilo, alquilarilo, arilalquilo, hidroxialquilo, carboxamida, CO2H, -(CH2)qOH, -(CH2)qOR31, -(CH2)qNHR31, - (CH2)qN(R31)2, -OR30, halogeno, = O, y -C(=O)R31; R12 se selecciona del grupo que consiste en H, alquilo, -CN, -C(=O)N(R30)2, -(CH2)qOH, -(CH2)qOR31, -(CH2)qNHR31, -(CH2)qN(R31)2), y -S(O2)R31; los restos R20 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo que consiste en H, alquilo, alquenilo, alquilarilo, alquinilo, alcoxi, alquilamino, alquiltiocarboxi, alquilheteroarilo, alquiltio, alquilsulfinilo, alquilsulfonilo, alcoxicarbonilo, aminoalquilo, amidinilo, aralquilo, aralquenilo, aralcoxi, aralcoxicarbonilo, aralquiltio, arilo, aroilo, ariloxi, ciano, cicloalquilo, cicloalquenilo, formilo, guanidinilo, halogeno, haloalquilo, haloalcoxi, heteroalquilo, heteroarilo, heterociclilo, heterociclenilo, hidroxialquilo, hidroxamato, nitro, trifluormetilo, trifluormetoxi, -(CH2)qOH, -(CH2)qOR31, -(CH2)qNH2, -(CH2)qNHR31, -(CH2)qN(R31)2, -(CH2)qC(=O)NHR31, -(CH2)qSO2R31, -(CH2)qNHSO2R31, -(CH2)qSO2NHR31, - alquinilC(R31)2OR31, -C(=O)R30, -C(=O)N(R30)2, -C(=NR30)NHR30, -C(=NOH)N(R30)2, -C(=NOR31)N(R30)2, -C(=O)OR30, -N(R30)2, -N(R30)C(=O)R31, -NHC(=O)N(R30)2, -N(R30)C(=O)OR31, -N(R30)C(=NCN)N(R30)2, -N(R30)C(=O)N(R30)SO2(R31), -N(R30)C(=O)N(R30)2, - N(R30)SO2(R31), -N(R30)S(O)2N(R30)2, -OR30, -OC(=O)N(R30)2, -SR30, -SO2N(R30)2, -SO2(R31), -OSO2(R31), y -OSi(R30)3; o alternativamente se vinculan juntos dos restos R20 para formar un anillo, arilo, cicloalquilo, heterociclilo, heterociclenilo, o heteroarilo de cinco o seis miembros donde dicho anillo arilo, cicloalquilo, heterociclilo, heterociclenilo, o heteroarilo de cinco o seis miembros se fusiona al anillo D y el anillo fusionado se sustituye en forma opcional con 0-4 restos R21; los restos R21 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo que consiste en H, alquilo, alquenilo, alquilarilo, alquinilo, alcoxi, alquilamino, alquiltiocarboxi, alquilheteroarilo, alquiltio, alquilsulfinilo, alquilsulfonilo, alcoxicarbonilo, aminoalquilo, amidinilo, aralquilo, aralquenilo, aralcoxi, aralcoxicarbonilo, aralquiltio, arilo, aroilo, ariloxi, ciano, cicloalquilo, cicloalquenilo, formilo, guanidinilo, halogeno, haloalquilo, haloalcoxi, heteroalquilo, heteroarilo, heterociclilo, heterociclenilo, hidroxialquilo, hidroxamato, nitro, trifluormetoxi, -(CH2)qOH, -(CH2)qOR31, -(CH2)qNH2, -(CH2)qNHR31, -(CH2)qN(R31)2, -(CH2)qC(=O)NHR31, -(CH2)qSO2R31, -(CH2)qNHSO2R31, - (CH2)qSO2NHR31, -alquinilC(R31)2OR31, -C(=O)R30, -C(=O)N(R30)2, -C(=NR30)NHR30, -C(=NOH)N(R30)2, -C(=NOR31)N(R30)2, -C(=O)OR30, -N(R30)2, -N(R30)C(=O)R31, -NHC(=O)N(R30)2, -N(R30)C(=O)OR31, -N(R30)C(=NCN)N(R30)2, -N(R30)C(=O)N(R30)SO2(R31), - N(R30)C(=O)N(R30)2, -N(R30)SO2(R31), -N(R30)S(O)2N(R30)2, -OR30, -OC(=O)N(R30)2, -SR30, -SO2N(R30)2, -SO2(R31), -OSO2(R31), y -OSi(R30)3; Y se selecciona del grupo que consiste en -(CR13R13)r-, -CHR13C(=O)-, -(CHR13)rO-, -(CHR13)r N(R30)-, -C(=O)-, - C(=NR30)-, -C(=N-OR30)-, -CH(C(=O)NHR30)-, CH-heteroaril-, -C(R13R13)rC(R13)=C(R13)-, -(CHR13)rC(=O)- y -(CHR13)rN(H)C(=O)-; o alternativamente Y es Cicloalquilo, heterociclenilo, o heterociclilo donde el cicloalquilo, heterociclenilo, o heterociclilo se fusiona con el anillo D; los restos R13 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo que consiste en H, alquilo, alquilarilo, cicloalquilo, alcoxi, arilo, heteroarilo, heterociclenilo, heterociclilo, espiroalquilo, -CN, -CO2H, -C(=O)R30, -C(=O)N(R30)2, -(CHR30)qOH, -(CHR30)qOR31, -(CHR30)qNH2, -(CHR30)qNHR31, -(CH2)qC(=O)NHR31, -(CH2)qSO2R31, -(CH2)qNSO2R31, -(CH2)qSO2NHR31, -NH2, -N(R30)2, -N(R30)C(=O)N(R30)2, -N(R30)SO2(R31), - OH, OR30 , -SO2N(R30)2, y -SO2(R31); los restos R30 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo que consiste en H, alquilo, alquilarilo, arilo, aralquilo, cicloalquilo, CN, -(CH2)qOH, -(CH2)qOalquilo, - (CH2)qOalquilarilo, -(CH2)COarilo, -(CH2)qOaralquilo, -(CH2)qOcicloalquilo, -(CH2)qNH2, -(CH2)qNHalquilo, -(CH2)qN(alquil)2, -(CH2)qNHalquilarilo, -(CH2)qNHarilo, -(CH2)qNHaralquilo, -(CH2)qNHcicloalquilo, -(CH2)qC(=O)NHalquilo, - (CH2)qC(=O)N(alquil)2, - (CH2)qC(=O)NHalquilarilo, -(CH2)qC(=O)NHarilo, -(CH2)qC(=O)NHaralquilo, -(CH2)qC(=O)NHcicloalquilo, -(CH2)qSO2alquilo, -(CH2)qSO2alquilarilo, -(CH2)qSO2arilo, -(CH2)qSO2aralquilo, -(CH2)qSO2cicloalquilo, -(CH2)qNSO2alquilo, - (CH2)qNSO2alquilarilo, -(CH2)qNSO2arilo, -(CH2)qNSO2aralquilo, -(CH2)qNSO2cicloalquilo, -(CH2)qSO2NHalquilo, -(CH2)qSO2NHalquilarilo, -(CH2)qSO2NHarilo, -(CH2)qSO2NHaralquilo, -(CH2)qSO2NHcicloalquilo, heterociclenilo, heterociclilo, y heteroarilo; los restos R31 pueden ser iguales o diferentes, seleccionándose cada uno en forma independiente del grupo que consiste en alquilo, alquilarilo, arilo, aralquilo, cicloalquilo, -(CH2)qOH, -(CH2)qOalquilo, -(CH2)qOalquilarilo, -(CH2)qOarilo, - (CH2)qOaralquilo, -(CH2)qOcicloalquilo, -(CH2)qNH2, -(CH2)qNHalquilo, -(CH2)qN(alquilo)2, -(CH2)qNHalquilarilo, -(CH2)qNHarilo, -(CH2)qNHaralquilo, -(CH2)qNHcicloalquilo, -(CH2)qC(=O)NHalquilo, -(CH2)qC(=O)N(alquilo)2, -(CH2)qC(=O)NHalquilarilo, - (CH2)qC(=O)NHarilo, -(CH2)qC(=O)NHaralquilo, -(CH2)qC(=O)NHcicloalquilo, -(CH2)qSO2alquilo, -(CH2)qSO2alquilarilo, -(CH2)qSO2arilo, -(CH2)qSO2aralquilo, -(CH2)qSO2cicloalquilo, -(CH2)qNSO2alquilo, - (CH2)qNSO2alquilarilo, -(CH2)qNSO2arilo, - (CH2)qNSO2aralquilo, -(CH2)qNSO2cicloalquilo, -(CH2)qSO2NHalquilo, -(CH2)qSO2NHalquilarilo, -(CH2)qSO2NHarilo, -(CH2)qSO2NHaralquilo, -(CH2)qSO2NHcicloalquilo, heterociclenilo, heterociclilo, y heteroarilo; m es 0 a 4; n es 0 a 4; cada q puede ser igual o diferente, seleccionándose cada uno en forma independiente de 1 a 5; y r es 1 a 4; con la condicion de que no hayan dos dobles enlaces adyacentes en ningun anillo, y que cuando se sustituye un nitrogeno mediante dos grupos alquilo, dichos dos grupos alquilo puedan opcionalmente unirse uno al otro para formar un anillo.
ARP060100550A 2005-02-16 2006-02-15 Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3 AR053020A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65347705P 2005-02-16 2005-02-16

Publications (1)

Publication Number Publication Date
AR053020A1 true AR053020A1 (es) 2007-04-18

Family

ID=36617152

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100550A AR053020A1 (es) 2005-02-16 2006-02-15 Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3

Country Status (13)

Country Link
US (1) US7879838B2 (es)
EP (1) EP1858888B1 (es)
JP (1) JP2008530213A (es)
KR (1) KR20070107040A (es)
CN (1) CN101189225A (es)
AR (1) AR053020A1 (es)
AU (1) AU2006216941B2 (es)
CA (1) CA2598418A1 (es)
IL (1) IL185071A0 (es)
MX (1) MX2007009949A (es)
TW (1) TWI318977B (es)
WO (1) WO2006091428A2 (es)
ZA (1) ZA200706588B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027076A1 (en) 2003-09-09 2007-02-01 Fumapham Ag Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
NZ550370A (en) 2004-04-13 2009-09-25 Incyte Corp Piperazinylpiperidine derivatives as chemokine receptor antagonists
EP1856097B1 (en) * 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
TW200714610A (en) 2005-02-16 2007-04-16 Univ Maryland CXCR3 is a gliadin receptor
US7417045B2 (en) * 2005-02-16 2008-08-26 Schering Corporation Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
KR20070107046A (ko) * 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 지닌 헤테로사이클릭 치환된피페라진
WO2006088921A2 (en) * 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
MX2007010068A (es) * 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
WO2007047202A1 (en) * 2005-10-11 2007-04-26 Schering Corporation Substituted heterocyclic compounds with cxcr3 antagonist activity
JP2009530383A (ja) * 2006-03-21 2009-08-27 シェーリング コーポレイション Ｃｘｃｒ３拮抗活性を有する、新規ヘテロ環ピリジン置換体
CN101516869A (zh) * 2006-07-14 2009-08-26 先灵公司 具有cxcr3拮抗剂活性的杂环取代的哌嗪化合物
EP2094688A1 (en) * 2006-12-22 2009-09-02 Schering Corporation Heterocyclic compounds with cxcr3 antagonist activity
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
PL2137537T3 (pl) 2007-02-08 2013-10-31 Biogen Ma Inc Kompozycje i zastosowania do leczenia stwardnienia rozsianego
JP2008222603A (ja) * 2007-03-09 2008-09-25 Institute Of Physical & Chemical Research 神経変性疾患の予防・治療剤
US8367052B2 (en) 2007-03-26 2013-02-05 General Regeneratives Holdings Inc. Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
CA2727174A1 (en) * 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
CA2775840C (en) 2009-10-01 2018-02-06 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CN103037843A (zh) 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
US9095591B2 (en) 2010-06-28 2015-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Pharmaceutical composition for use in the treatment of glaucoma
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EA027595B1 (ru) 2012-02-02 2017-08-31 Актелион Фармасьютиклз Лтд. 4-(бензоимидазол-2-ил)тиазольные соединения и родственные азапроизводные
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
WO2015011099A1 (en) 2013-07-22 2015-01-29 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
UA119805C2 (uk) 2015-01-15 2019-08-12 Ідорсія Фармасьютікалз Лтд Похідні гідроксіалкілпіперазину як модулятори cxcr3-рецептора
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
KR101828240B1 (ko) 2016-10-17 2018-02-13 (주)네오팜 항염용 조성물
KR101828241B1 (ko) * 2016-10-17 2018-02-13 (주)네오팜 항염용 조성물
US10722499B2 (en) 2017-01-06 2020-07-28 Palvella Therapeutics, Inc. Anyhydrous compositions of mTOR inhibitors and methods of use
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
CN114702440B (zh) * 2022-04-26 2024-06-18 永农生物科学有限公司 一种氨氯吡啶酸的制备方法及制备的氨氯吡啶酸

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2915892A (en) 1991-11-14 1993-06-15 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
WO1993014077A1 (en) 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
US20020018776A1 (en) 2000-04-14 2002-02-14 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CXCR3 function
JP4259877B2 (ja) 2000-12-11 2009-04-30 アムジエン・インコーポレーテツド Ｃｘｃｒ３アンタゴニスト
US6642226B2 (en) * 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
US20050119174A1 (en) 2002-04-03 2005-06-02 Sumitomo Pharmaceuticals Co. Ltd. Novel blood sugar controller and method of screening the same
US7244555B2 (en) 2002-05-14 2007-07-17 Renovak Inc Systems and methods for identifying organ transplant risk
WO2003101970A1 (en) 2002-06-03 2003-12-11 Smithkline Beecham Corporation Imidazolium cxcr3 inhibitors
MXPA05013474A (es) 2003-06-13 2006-03-09 Schering Ag Derivados de quinolilamida como antagonistas de ccr-5.
WO2006088921A2 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
MX2007010068A (es) 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
EP1856097B1 (en) 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
EP1853583B1 (en) 2005-02-16 2011-09-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
US7417045B2 (en) 2005-02-16 2008-08-26 Schering Corporation Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
KR20070107046A (ko) 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 지닌 헤테로사이클릭 치환된피페라진
WO2007047202A1 (en) * 2005-10-11 2007-04-26 Schering Corporation Substituted heterocyclic compounds with cxcr3 antagonist activity
JP2009530383A (ja) 2006-03-21 2009-08-27 シェーリング コーポレイション Ｃｘｃｒ３拮抗活性を有する、新規ヘテロ環ピリジン置換体
CN101516869A (zh) 2006-07-14 2009-08-26 先灵公司 具有cxcr3拮抗剂活性的杂环取代的哌嗪化合物
EP2094688A1 (en) 2006-12-22 2009-09-02 Schering Corporation Heterocyclic compounds with cxcr3 antagonist activity

Also Published As

Publication number Publication date
EP1858888A2 (en) 2007-11-28
MX2007009949A (es) 2007-09-26
US20060276448A1 (en) 2006-12-07
TW200640906A (en) 2006-12-01
ZA200706588B (en) 2008-09-25
US7879838B2 (en) 2011-02-01
WO2006091428A2 (en) 2006-08-31
IL185071A0 (en) 2007-12-03
AU2006216941A1 (en) 2006-08-31
KR20070107040A (ko) 2007-11-06
JP2008530213A (ja) 2008-08-07
TWI318977B (en) 2010-01-01
CA2598418A1 (en) 2006-08-31
AU2006216941B2 (en) 2009-12-03
EP1858888B1 (en) 2013-04-17
CN101189225A (zh) 2008-05-28
WO2006091428A3 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
AR053020A1 (es) Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3
AR054224A1 (es) Piperazin- piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3
AR055195A1 (es) Piperazin-piridinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3 y composicion farmaceutica
AR054185A1 (es) Piperazin- piperidinas sustituidas con piridilo y fenilo conectados por aminos con actividad antagonista de cxcr3
AR064609A1 (es) Piperazinas sustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor de quimiocinas cxcr3.
AR052911A1 (es) Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3
AR059962A1 (es) Compuestos de piridina sustituida con heterociclos con actividad antagonista de cxcr3
AR047448A1 (es) Compuestos derivados de acidos fosfinicos y fosfonicos que poseen actividad inhibitoria de serina proteasa y su uso en la preparacion de un medicamento para el tratamiento de trastornos mediados por la quimasa.
AR045260A1 (es) Compuestos que contienen imidazo-oxima sustituidos
AR045387A1 (es) Compuestos bencimidazolil n-sustituidos inhibidores de c-kit; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de un trastorno proliferativo
PE20080067A1 (es) DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR)
CY1112601T1 (el) Υποκατεστημενα παραγωγα 1-πιπεριδιν-4-υλ-4-πυρρολιδιν-3-υλ-πιπεραζινης και χρηση αυτων ως ανταγωνιστων νευροκινινης
AR069174A1 (es) Derivados de pirazolo[3,4-b]-piridina inhibidores de proteinquinasas, procesos de preparacion, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias o proliferativas.
AR070274A1 (es) Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR049333A1 (es) Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
AR035670A1 (es) Imidazopiridinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
AR057104A1 (es) Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica
AR049652A1 (es) Sales cuaternarias antagonistas del receptor ccr2
ECSP066886A (es) Compuestos y métodos para el tratamiento de dislipidemia
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
EA201100975A1 (ru) Производные 1,2,4-оксадиазола и их применение в терапии
CO6251283A2 (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
PE20050090A1 (es) Indol-3-carboxamidas como activadores de glocoquinasa
EA200400306A1 (ru) 2-амино-4,5-тризамещенные производные тиазолила
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal